Express News | Esperion Therapeutics Inc - No Serious Adverse Events Observed in Bempedoic Acid Trial

ReutersNov 26 08:00 ET

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

GlobeNewswireNov 26 08:00 ET

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

GlobeNewswireNov 21 08:00 ET

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsNov 19 06:31 ET · Ratings

Esperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who...

BenzingaNov 18 10:31 ET

US Manufacturing Index Rises To 43, Highest Since 2020

Business TodayNov 16 02:13 ET